[1] GRIFFITHS C E, BARKER J N．Pathogenesis and clinical features of psoriasis [J]．Lancet, 2007, 370(9583): 263-271．
[2] MAGRO C, CHENG E, KLINE M A, et al．Follicular psoriasis: a report of 5 cases and review of the literature,likely an under-recognized yet distinctive variant of psoriasis[J]．Dermatol Online J, 2020, 26(7): 13030．
[3] MENTER A, GOTTLIEB A, FELDMAN S R, et al．Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics[J]．J Am Acad Dermatol, 2008, 58(5): 826-850．
[4] TORSEKAR R, GAUTAM M M．Topical therapies in psoriasis [J]．Indian Dermatol Online J, 2017, 8(4): 235-245．
[5] TAKAHASHI H, IBE M, KINOUCHI M, et al．Similarly potent action of 1,25-dihydroxyvitamin D3 and its analogues,tacalcitol, calcipotriol, and maxacalcitol on normal human keratinocyte proliferation and differentiation [J]．J Dermatol Sci, 2003, 31(1): 21-28．
[6] SARACENO R, GRAMICCIA T, FRASCIONE P, et al．Calcipotriene/betamethasone in the treatment of psoriasis:a review article [J]．Expert Opin Pharmacother, 2009,10(14): 2357-2365．
[7] 张 颖, 晋红中．钙泊三醇倍他米松软膏在银屑病治疗中的应用[J]．中华皮肤科杂志, 2014, 47(4): 293-295．
[8] DATE A A, NAIK B, NAGARSENKER M S．Novel drug delivery systems: potential in improving topical delivery of antiacne agents [J]．Skin Pharmacol Physiol, 2006, 19(1):2-16．
[9] GREYDANUS D E, AZMEH R, CABRAL M D, et al．Acne in the first three decades of life: an update of a disorder with profound implications for all decades of life [J]．Dis Mon, 2021, 67(4): 101103．
[10] PANDE V V, KADNOR N A, KADAM R N, et al．Fabrication and characterization of sertaconazole nitrate microsponge as a topical drug delivery system [J]．Indian J Pharm Sci, 2015, 77(6): 675-680．
[11] GANESH A, CHANDRAN S M P, APARNA P, et al．Microsponge — a novel drug delivery system: an overview[J]．Indo Am J Pharm Sci, 2018, 5(5): 4823-4830．
[12] SINGH B S, SAXENA S J．Fluorouracil-containing formulation: US, 2002165198A1 [P]．2002-11-07．
[13] 边 琼, 张福荣, 罗华菲, 等．微海绵给药系统在皮肤局部给药中的应用[J]．世界临床药物, 2017, 38(2): 128-133．
[14] PRINCE G T, CAMERON M C, RAMIN F, et al．Topical 5‐fluorouracil in dermatologic disease [J]．Int J Dermatol,2018, 57(10): 1259-1264．
[15] NAGULA R L, WAIRKAR S．Cellulose microsponges based gel of naringenin for atopic dermatitis: design,optimization, in vitro and in vivo investigation [J]．Int J Biol Macromol, 2020, 164: 717-725．
[16] SRIVASTAVA R, PATHAK K．Microsponges: a futuristic approach for oral drug delivery [J]．Expert Opin Drug Deliv, 2012, 9(7): 863-878．
[17] ABHALE S, AHIRE P, RAKIBE V D．A review on:microsponge loaded drug delivery system [J]．Novyi Mir,2021, 6(5): 213-224．
[18] VAN ZUUREN E J, ARENTS B W M, VAN DER LINDEN M M D, et al．Rosacea: new concepts in classification and treatment [J]．Am J Clin Dermatol, 2021, 22(4): 457-465．
[19] SCHALLER M, ALMEIDA L M C, BEWLEY A, et al．Recommendations for rosacea diagnosis, classification and management: update from the global ROSacea Consensus2019 panel [J]．Br J Dermatol, 2020, 182(5): 1269-1276．
[20] GALLO R L, GRANSTEIN R D, KANG S, et al．Standard classification and pathophysiology of rosacea: the 2017 update by the National Rosacea Society Expert Committee[J]．J Am Acad Dermatol, 2018, 78(1): 148-155．
[21] TWO A M, WU W, GALLO R L, et al．Rosacea: part Ⅱ.Topical and systemic therapies in the treatment of rosacea[J]．J Am Acad Dermatol, 2015, 72(5): 761-770．
[22] ABOKWIDIR M, FELAMAN S R．Rosacea management[J]．Skin Appendage Disorders, 2016, 2(1/2): 26-34．
[23] ZAENGLEIN A L, PATHY A L, SCHLOSSER B J, et al．Guidelines of care for the management of acne vulgaris[J]．J Am Acad Dermatol, 2016, 74(5): 945-973．
[24] ROSSO J Q．Oral doxycycline in the management of acne vulgaris: current perspectives on clinical use and recent
findings with a new double-scored small tablet formulation[J]．J Clin Aesthet Dermatol, 2015, 8(5): 19-26．
[25] OCHSENDORF F．Minocycline in acne vulgaris: benefits and risks [J]．Am J Clin Dermatol, 2010, 11(5): 327-341．
[26] TAMARKIN D, GAZAL E, PAPIASHVILI I, et al．Topical tetracycline compositions: US, 2020261586A1 [P]．2020-08-20．
[27] HADLEY G R, GAYLE J A, RIPOLL J, et al．Post-herpetic neuralgia: a review [J]．Curr Pain Headache Rep, 2016,20(3): 17．
[28] JOHNSON R W．Herpes zoster and postherpetic neuralgia[J]．Expert Rev Vaccines, 2010, 9(3 Suppl): 21-26．
[29] SAMPATHKUMAR P, DRAGE L A, MARTIN D P．Herpes zoster(shingles) and postherpetic neuralgia [J]．Mayo Clin Proc, 2009, 84(3): 274-280．
[30] ARGOFF C E, KATZ N, BACKONJA M．Treatment of postherpetic neuralgia: a review of therapeutic options [J]．J Pain Symptom Manage, 2004, 28(4): 396-411．
[31] 周 淼, 李 祥．带状疱疹后遗神经痛的药物治疗及预防研究进展[J]．中国中西医结合皮肤性病学杂质, 2020,19(5): 489-493．
[32] MALONEY J, PEW S, WIE C, et al．Comprehensive review of topical analgesics for chronic pain [J]．Curr Pain Headache Rep, 2021, 25(2): 7．
[33] MORI T, SAIDA N．Non-aqueo u s p a t c h : US,2021038531A1 [P]．2021-02-11．